Surface expression of CD-4 does not predict susceptibility to infection with HIV-1 in human monocyte hybridomas.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Surface expression of CD-4 does not predict susceptibility to infection with HIV-1 in human monocyte hybridomas.

J Clin Lab Immunol. 1990 Apr;31(4):151-6. Unique Identifier : AIDSLINE MED/93021026
Sperber K; Shaked A; Posnett DN; Hirschman SZ; Bekesi G; Mayer L; Division of Clinical Immunology, Mount Sinai, Medical Center, New; York, New York 10029.

Abstract: In contrast to T-cell lines, where CD-4 expression may predict susceptibility to HIV infection, in monocyte hybridomas, presence or absence of surface CD-4 does not appear to be the determining factor of susceptibility to HIV infection. One clone, 20, was documented to be CD-4 negative by surface immunofluorescence as well as by immunoprecipitation. Both CD-4+ and CD-4- human monocyte hybridomas, representative of peripheral blood monocytes were readily infected with HIV (strains IIIB and BR-1 and a variety of patient isolates) as assessed by p24 Ag secretion reverse transcriptase activity and in situ hybridization. Infection occurred in the absence of antibody to HIV suggesting a non Fc mediated process as had been previously described. These data suggest that alternative mechanisms, such as non-specific phagocytosis, may exist for entry of HIV into peripheral blood monocytes. Given these findings, treatment for AIDS, such as the use of soluble CD-4, may not be effective long term, as monocyte infection may still occur and serve as a reservoir for subsequent viral infection of T cells.

Keywords: Antigens, CD4/*ANALYSIS/PHYSIOLOGY Comparative Study Human Hybridomas/IMMUNOLOGY/*MICROBIOLOGY HIV-1/*PHYSIOLOGY Interferon Type II/PHARMACOLOGY Leukocytes, Mononuclear/DRUG EFFECTS/IMMUNOLOGY/MICROBIOLOGY Lymphocyte Transformation Lymphoma, Large-Cell, Diffuse/PATHOLOGY Phagocytosis Receptors, HIV Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. Tumor Cells, Cultured/IMMUNOLOGY/MICROBIOLOGY JOURNAL ARTICLE
930130
M9311178

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .